Changing it Up

Drug discovery is harder than it used to be, says Technology Review's Susan Young. Pharma pipelines are freezing up and fewer drugs are getting past early-stage testing. Further, there are entrepreneurs who have new ideas, but no money to bring them to completion, Young says. So pharma, biotech, and academia are trying to solve their collective problems by coming together with venture capitalists to create new drug discovery funding models, she adds.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.